Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. BDRX
stocks logo

BDRX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2019Q4
--
--
-20000.000
-98.82%
Estimates Revision
The market is revising No Change the revenue expectations for Biodexa Pharmaceuticals Plc (BDRX) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -9.91%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Down
down Image
-9.91%
In Past 3 Month

Valuation Metrics

The current forward P/E ratio for Biodexa Pharmaceuticals PLC (BDRX.O) is -15.28, compared to its 5-year average forward P/E of -52.89. For a more detailed relative valuation and DCF analysis to assess Biodexa Pharmaceuticals PLC 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-52.89
Current PE
-15.28
Overvalued PE
126.72
Undervalued PE
-232.50

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-1.32
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
1.45
Undervalued EV/EBITDA
-4.09

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
45.53
Current PS
0.00
Overvalued PS
134.30
Undervalued PS
-43.25
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

BDRX News & Events

Events Timeline

(ET)
2025-12-01
08:41:00
Biodexa Enrolls First Patients in Phase 3 Serenta Trial of eRapa for Colorectal Cancer
select
2025-11-24 (ET)
2025-11-24
08:42:25
Biodexa Pharmaceuticals Launches First European Site for Phase 3 Serenta Study
select
2025-11-03 (ET)
2025-11-03
08:34:39
Biodexa Receives EMA Approval for Phase 3 Trial CTA in FAP
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
2.0
11-24Newsfilter
Biodexa Activates First European Site for Phase 3 Serenta Trial in FAP
  • Trial Activation: Biodexa Pharmaceuticals has activated its first European site for the Phase 3 Serenta clinical trial at the University of Bonn, Germany, focusing on familial adenomatous polyposis (FAP). This milestone offers new hope for FAP patients who currently lack approved non-surgical treatment options.
  • Funding Support: The trial's launch is supported by a $20 million grant from the Cancer Prevention and Research Institute of Texas, along with collaborations with Emtora Biosciences and Precision for Medicine. This backing strengthens Biodexa's competitive position in the cancer treatment landscape in Europe.
  • Trial Design: The Serenta trial is a randomized, double-blind, placebo-controlled study aimed at evaluating the efficacy of eRapa in preventing disease progression in FAP patients. Given that untreated FAP leads to colorectal cancer in nearly all patients by age 50, the trial's success could significantly enhance patient quality of life.
  • Future Plans: Nine additional European sites are expected to activate over the next 2-3 months across the Netherlands, Spain, Denmark, and Italy. This expansion will further bolster Biodexa's presence in the European market and provide treatment opportunities for more FAP patients.
[object Object]
Preview
8.5
09-27SeekingAlpha
Biodexa Pharmaceuticals submits $100M shelf registration for versatile securities sales

  • Biodexa Pharmaceuticals Filing: Biodexa Pharmaceuticals has filed a $100 million shelf registration with the SEC for future offerings of various securities.

  • Types of Securities: The securities may include ordinary shares, ADS representing ordinary shares, debt securities, warrants, rights, and units.

[object Object]
Preview
9.5
09-12SeekingAlpha
Biodexa Pharmaceuticals Reports GAAP EPS of £0.00

  • Earnings Report: Biodexa Pharmaceuticals reported a GAAP EPS of £0.00 for the first half of the year.

  • Quant Rating: Seeking Alpha has provided a Quant Rating for Biodexa Pharmaceuticals, indicating an analysis of the company's performance.

  • Historical Data: The press release includes references to historical earnings data for Biodexa Pharmaceuticals, suggesting a review of past financial performance.

  • Financial Information: Additional financial information regarding Biodexa Pharmaceuticals is available, likely detailing various aspects of the company's financial health.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Biodexa Pharmaceuticals PLC (BDRX) stock price today?

The current price of BDRX is 5.09 USD — it has increased 3.67 % in the last trading day.

arrow icon

What is Biodexa Pharmaceuticals PLC (BDRX)'s business?

Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company. The Company is developing a pipeline of products for the treatment of diseases with unmet medical needs. The Company’s lead development program, eRapa, is under development for familial adenomatous polyposis and non-muscle invasive bladder cancer; tolimidone, under development as a for the treatment of type 1 diabetes; and MTX110, which is being studied in aggressive rare/orphan brain cancer indications, including recurrent glioblastoma, diffuse midline glioma, or DMG, and medulloblastoma. Its technologies include Q-Sphera, MidaCore and MidaSolve. The Q-Sphera platform is a polymer microsphere microtechnology used for sustained delivery to prolong and control the release of therapeutics over an extended period of time, from weeks to months. Its MidaSolve platform is an oligosaccharide nanotechnology that is used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors.

arrow icon

What is the price predicton of BDRX Stock?

Wall Street analysts forecast BDRX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for BDRX is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Biodexa Pharmaceuticals PLC (BDRX)'s revenue for the last quarter?

Biodexa Pharmaceuticals PLC revenue for the last quarter amounts to NaN USD, decreased % YoY.

arrow icon

What is Biodexa Pharmaceuticals PLC (BDRX)'s earnings per share (EPS) for the last quarter?

Biodexa Pharmaceuticals PLC. EPS for the last quarter amounts to USD, decreased % YoY.

arrow icon

What changes have occurred in the market's expectations for Biodexa Pharmaceuticals PLC (BDRX)'s fundamentals?

The market is revising No Change the revenue expectations for Biodexa Pharmaceuticals Plc (BDRX) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -9.91%.
arrow icon

How many employees does Biodexa Pharmaceuticals PLC (BDRX). have?

Biodexa Pharmaceuticals PLC (BDRX) has 16 emplpoyees as of December 05 2025.

arrow icon

What is Biodexa Pharmaceuticals PLC (BDRX) market cap?

Today BDRX has the market capitalization of 3.15M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free